227 related articles for article (PubMed ID: 21693061)
1. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor.
Cocco E; Varughese J; Buza N; Bellone S; Glasgow M; Bellone M; Todeschini P; Carrara L; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Lockwood CJ; Santin AD
BMC Cancer; 2011 Jun; 11():263. PubMed ID: 21693061
[TBL] [Abstract][Full Text] [Related]
2. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma.
Cocco E; Hu Z; Richter CE; Bellone S; Casagrande F; Bellone M; Todeschini P; Krikun G; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Buza N; Pecorelli S; Lockwood CJ; Santin AD
Br J Cancer; 2010 Sep; 103(6):812-9. PubMed ID: 20700124
[TBL] [Abstract][Full Text] [Related]
3. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.
Cocco E; Varughese J; Buza N; Bellone S; Lin KY; Bellone M; Todeschini P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Carrara L; Tassi R; Pecorelli S; Lockwood CJ; Santin AD
Clin Exp Metastasis; 2011 Oct; 28(7):689-700. PubMed ID: 21725665
[TBL] [Abstract][Full Text] [Related]
4. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.
Varughese J; Cocco E; Bellone S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Buza N; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2011 Dec; 205(6):567.e1-7. PubMed ID: 21889762
[TBL] [Abstract][Full Text] [Related]
5. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
[TBL] [Abstract][Full Text] [Related]
6. [Global expression analysis in uterine cervical cancer: metabolic pathways and altered genes].
Vázquez-Ortíz G; Piña-Sanchez P; Hidalgo A; Lazos M; Moreno J; Alvarado I; Cruz F; Hernández DM; Pérez-Plascencia C; Salcedo M
Rev Invest Clin; 2005; 57(3):434-41. PubMed ID: 16187704
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
[TBL] [Abstract][Full Text] [Related]
8. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.
Varughese J; Cocco E; Bellone S; Bellone M; Todeschini P; Carrara L; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Gynecol Oncol; 2011 Jul; 122(1):171-7. PubMed ID: 21453957
[TBL] [Abstract][Full Text] [Related]
9. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
Zeybek B; Manzano A; Bianchi A; Bonazzoli E; Bellone S; Buza N; Hui P; Lopez S; Perrone E; Manara P; Zammataro L; Altwerger G; Han C; Tymon-Rosario J; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin A
Sci Rep; 2020 Jan; 10(1):973. PubMed ID: 31969666
[TBL] [Abstract][Full Text] [Related]
10. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.
Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS
Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640
[TBL] [Abstract][Full Text] [Related]
11. The synergic effect of HPV infection and epigenetic anomaly of the p16 gene in the development of cervical cancer.
Ahmad A; Raish M; Shahid M; Batra S; Batra V; Husain SA
Cancer Biomark; 2017 Jul; 19(4):375-381. PubMed ID: 28453456
[TBL] [Abstract][Full Text] [Related]
12. Impact of sampling origin on molecular detection of high-risk human papillomavirus and oncogene expression.
Kahla S; Achour M; Oueslati S; Kochbati L; Chanoufi MB; Maalej M; Oueslati R
Eur J Gynaecol Oncol; 2012; 33(2):187-92. PubMed ID: 22611961
[TBL] [Abstract][Full Text] [Related]
13. Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.
Varughese J; Cocco E; Bellone S; de Leon M; Bellone M; Todeschini P; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2011 Jul; 117(14):3163-72. PubMed ID: 21246534
[TBL] [Abstract][Full Text] [Related]
14. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII.
Koizume S; Jin MS; Miyagi E; Hirahara F; Nakamura Y; Piao JH; Asai A; Yoshida A; Tsuchiya E; Ruf W; Miyagi Y
Cancer Res; 2006 Oct; 66(19):9453-60. PubMed ID: 17018600
[TBL] [Abstract][Full Text] [Related]
15. Unique microRNA expression profiles in cervical cancer.
Gocze K; Gombos K; Juhasz K; Kovacs K; Kajtar B; Benczik M; Gocze P; Patczai B; Arany I; Ember I
Anticancer Res; 2013 Jun; 33(6):2561-7. PubMed ID: 23749909
[TBL] [Abstract][Full Text] [Related]
16. Biological and clinical significance of NAC1 expression in cervical carcinomas: a comparative study between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas.
Yeasmin S; Nakayama K; Rahman MT; Rahman M; Ishikawa M; Katagiri A; Iida K; Nakayama N; Otuski Y; Kobayashi H; Nakayama S; Miyazaki K
Hum Pathol; 2012 Apr; 43(4):506-19. PubMed ID: 21889186
[TBL] [Abstract][Full Text] [Related]
17. [Expression of RASSF1A mRNA and its relationship with HPV-16 in cervical cancer].
Zhang SL; Li N; Ma L; Jiang T
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(41):2916-9. PubMed ID: 16324365
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
[TBL] [Abstract][Full Text] [Related]
19. Impact of HPV 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy - A prospective observational study.
Mahantshetty U; Teni T; Naga P; Hotwani C; Umesh S; Kannan S; Hande V; Pawar S; Engineer R; Chopra S; Deodhar K; Maheshwari A; Gurram L; Gupta S; Shrivastava SK
Gynecol Oncol; 2018 Feb; 148(2):299-304. PubMed ID: 29203175
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling in two morphologically different uterine cervical carcinoma cell lines derived from a single donor using a human cancer cDNA array.
Fujimoto T; Nishikawa A; Iwasaki M; Akutagawa N; Teramoto M; Kudo R
Gynecol Oncol; 2004 May; 93(2):446-53. PubMed ID: 15099960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
